Table 1.
Characteristics of Korean mRCC patients
| Characteristic | No. (%) |
|---|---|
| Median age (range, yr) | 58.1 (29-83) |
| Gender | |
| Male | 80 (80) |
| Female | 20 (20) |
| Tumor histology | |
| Clear cell type | 86 (86) |
| Non-clear cell type | 14 (14) |
| Any sarcomatoid features (n=84, nephrectomy cases) | |
| Yes | 10 (10) |
| No | 74 (74) |
| Initial VEGFr-TKI therapy | |
| Sunitinib | 73 (73) |
| Sorafenib | 17 (17) |
| Pazopanib | 10 (10) |
| No. of previous VEGFr-TKI therapies | |
| 1 | 81 (81) |
| ≥ 2 | 19 (19) |
| KPS | |
| 100-90 | 22 (2) |
| 80-70 | 74 (74) |
| 60-50 | 4 (4) |
| Previous nephrectomy | |
| Yes | 84 (84) |
| No | 16 (16) |
| Previous immunotherapy | |
| Yes | 20 (20) |
| No | 80 (80) |
| No. of metastatic sites | |
| ≤ 1 | 16 (16) |
| ≥ 2 | 84 (84) |
| Heng’s criteriaa) | |
| Favorable | 8 (8) |
| Intermediate | 64 (64) |
| Poor | 23 (23) |
| Not applicable | 5 (5) |
mRCC, metastatic renal cell carcinoma; VEGFr-TKI, vascular endothelial growth factorreceptor-tyrosine kinase inhibitor; KPS, Karnofsky performance scale.
a)
Heng’s prognostic criteria: low KPS score < 80, low hemoglobin (< lower limit of normal), high corrected serum calcium concentration (> upperlimit of normal), high platelet count (> upper limit of normal), high neutrophil count (> upper limit of normal), time from diagnosis to treatment < 1 year. Categories are defined as favorable=0, intermediate=1-2, or poor=3-6 risk factors.